Back to top
more

Fulgent Genetics (FLGT)

(Delayed Data from NSDQ)

$20.67 USD

20.67
292,801

-0.11 (-0.53%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $20.68 +0.01 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 51.11% and 6.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Nyxoah SA (NYXH): Can Its 10.2% Jump Turn into More Strength?

by Zacks Equity Research

Nyxoah SA (NYXH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Are Medical Stocks Lagging Fulgent Genetics (FLGT) This Year?

by Zacks Equity Research

Here is how Fulgent Genetics, Inc. (FLGT) and Harrow Health (HROW) have performed compared to their sector so far this year.

Zacks Equity Research

Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Fulgent Genetics, Inc. (FLGT) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

Zacks Equity Research

Is Fulgent Genetics (FLGT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Fulgent Genetics, Inc. (FLGT) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 14.29% and 13.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 88.24% and 1.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 6.85% and 2.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Fulgent Genetics, Inc. (FLGT) closed at $58, marking a -1.46% move from the previous day.

Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Fulgent Genetics, Inc. (FLGT) closed at $58.31, marking a +0.4% move from the previous day.

Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) closed the most recent trading day at $54.65, moving -0.35% from the previous trading session.

Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) closed the most recent trading day at $49.73, moving -0.4% from the previous trading session.

Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 14.12% and 6.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Computer Programs and Systems (CPSI) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Analysts Estimate Fullgent Genetics (FLGT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Fullgent Genetics (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Fulgent Genetics (FLGT) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Strategic investments and expanding operations in China are likely to have contributed to Fulgent Genetics' (FLGT) first-quarter performance.

Zacks Equity Research

Fullgent Genetics (FLGT) Stock Moves -1.28%: What You Should Know

by Zacks Equity Research

Fullgent Genetics (FLGT) closed at $56.44 in the latest trading session, marking a -1.28% move from the prior day.

Zacks Equity Research

Fullgent Genetics (FLGT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Fullgent Genetics (FLGT) closed at $61.50 in the latest trading session, marking a +0.87% move from the prior day.

Zacks Equity Research

Is Fulgent Genetics (FLGT) a Suitable Value Investor Stock?

by Zacks Equity Research

Let's see if Fulgent Genetics (FLGT) stock is a good choice for value-oriented investors right now from multiple angles.

Zacks Equity Research

Fullgent Genetics (FLGT) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Fullgent Genetics (FLGT) delivered earnings and revenue surprises of 25.56% and 31.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fulgent Genetics (FLGT) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

In terms of COVID-19 NGS revenues, Fulgent Genetics (FLGT) is expected to have witnessed a rise in testing volume on increased demand through the Q4 months.

Zacks Equity Research

Are These Medical Stocks a Great Value Stocks Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Fullgent Genetics (FLGT) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Fullgent Genetics (FLGT) closed at $65.84, marking a -0.98% move from the previous day.

Nitish Marwah headshot

4 Best Stocks With High Net Income Ratio to Grab Today

by Nitish Marwah

OPBK, BBW, EVRI, and FLGT qualified the screen for stocks with a high net income ratio.

Zacks Equity Research

Fullgent Genetics (FLGT) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Fullgent Genetics (FLGT) closed the most recent trading day at $71.50, moving +0.14% from the previous trading session.